Intravenous administration of magnesium and potassium solution lowers energy levels and increases success rates electrically cardioverting atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 1, 2012, Pages 54-59

  Sultan, Arian ^a   Steven, Daniel ^a   Rostock, Thomas ^a   Hoffmann, Boris ^a   MÜllerleile, Kai ^a   Servatius, Helge ^a   Drewitz, Imke ^a   LÜker, Jakob ^a   Meyer, Philip ^a   Salukhe, Tushar ^b   Willems, Stephan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

atrial fibrillation; bardioversion; biphasic shock; magnesium; potassium

Indexed keywords

MAGNESIUM; POTASSIUM;

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIAC PATIENT; CARDIOVERSION; CLINICAL PROTOCOL; CONTROLLED STUDY; ENERGY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; SYMPTOM; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; DEFIBRILLATORS; ELECTRIC COUNTERSHOCK; FEMALE; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM; MALE; MIDDLE AGED; POTASSIUM; TREATMENT OUTCOME;

EID: 84856018046     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02146.x     Document Type: Article

References (60)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG,: Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implication. Arch Intern Med 1995; 155:469- 473.
2. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rauthaharju PM,: Prevalence of atrial fibrillation in elderly subjects (The cardiovascular health study). Am J Cardiol 1994; 74: 236-241. (Pubitemid 24239044)
3. Bardy GH, Marchlinski FE, Sharma AD, Worley SJ, Luceri RM, Yee R, Hlperin BD, Fellows CL, Ahern TS, Chilson DA, Packer DL, Wilber DJ, Mattioni TA, Reddy R, Kronmal RA, Lazzara R,: Multicenter comparison of truncated biphasic shocks and damped sine wave monophasic shocks for transthoracic ventricular defibrillation. Transthoracic Investigators. Circulation 1996; 94: 2507-2514. (Pubitemid 26403580)
4. Ricard P, Imianitoff M, Saoudi N,: Cardioversion in atrial fibrillation. Rev Prat 2002; 52: 1313-1316. (Pubitemid 34717282)
5. DeCarli C, Sprouse G, LaRosa JC,: Serum magnesium levels in symptomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol 1986; 57: 956-999.
6. Gettes L,: Electrolyte abnormalities as triggers for lethal ventricular arrhythmias. In:, Akhtar M, Myerberg RJ, Ruskin JN, eds. Sudden Cardiac Death. Philadelphia: Williams & Wilkins, 1994, pp. 327-340.
7. Tsuij H, Venditti FJ, Evans JC, Larson MG, Levy M,: The associations of levels of serum potassium and magnesium with ventricular premature complexes (The Framingham Heart Study). Am J Cardiol 1994; 74: 232-235 (Pubitemid 24239043)
8. Fawcett WJ, Haxby EJ, Male DA,: Magnesium: Physiology and pharmacology. Br J Anaesth 1999; 83: 302-320. (Pubitemid 29361145)
9. Iseri LT, Allen BJ, Ginkel ML, Brodsky MA,: Ionic biology and ionic medicine in cardiac arrhythmias with particular reference to magnesium. Am Heart J 1992; 123: 1404-1419.
10. DiCarlo LA Jr, Morady F, de Buitleir M, Krol RB, Schurig L, Annesley TM,: Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol 1986; 7: 1356-1362. (Pubitemid 16100360)
11. Christiansen EH, Frost L, Andreasen F, Mortensen P, Thomsen PE, Pedersen AK,: Dose-related cardiac electrophysiological effects of intravenous magnesium. A double-blind placebo-controlled dose-response study in patients with paroxysmal supraventricular tachycardia. Europace 2000; 2: 320-326.
12. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH,; ESC Committee for Practice Guidelines (CPG);, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P,; Document Reviewers, Vardas PE, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlöf B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS); Authors/Task Force Members. Eur Heart J 2010.; 31: 2369-2429.
13. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board; Institute of Medicine; National Academy of Sciences: Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press, 1997. Available at:.
14. Solomon R,: The relationship between disorders of K and Mg2++ homeostasis. Semin Nephrol 1987; 7: 253-262.
15. Huang CL, Kuo E,: Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007; 18: 2649-2652. (Pubitemid 47531191)
16. Quamme GA,: Renal magnesium handling: New insights in understanding old problems. Kidney Int 1997; 52: 1180-1195. (Pubitemid 27496047)
17. Dai LJ, Friedman PA, Quamme GA,: Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 1997; 51: 1008-1017. (Pubitemid 27186524)
18. Whang R, Welt LA,: Observations in experimental magnesium depletion. J Clin Invest 1963; 42: 305-313.
19. Wong NLM, Sutton RA, Navichak V, Quame GA, Dirks JH,: Enhanced distal absorption of potassium by magnesium-deficient rats. Clin Sci 1985; 69: 626-639.
20. Link MS, Atkins DL, Passman RS, Halperin HR, Samson RA, White RD, Cudnik MT, Berg MD, Kudenchuk PJ, Kerber RE,: Part 6: Electrical therapies: Automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S706-S719. Review. Erratum in: Circulation 2011; 123:e235.
21. Page RL, Kerber RE, Russell JK, Trouton T, Waktare J, Gallik D, Olgin JE, Ricard P, Dalzell GW, Reddy R, Lazzara R, Lee K, Carlson M, Halperin B, Bardy GH,; BiCard Investigators: Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: The results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002; 39: 1956-1963. (Pubitemid 34628276)
22. Walcott GP, Killingsworth CR, Ideker RE,: Do clinically relevant transthoracic defibrillation energies cause myocardial damage and dysfunction Resuscitation 2003; 59: 59-70. (Pubitemid 37297979)
23. Waller C, Callies F, Langenfeld H,: Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes: Is external cardioversion contraindicated in patients with permanent pacing systems? Europace 2004; 6: 165-168. (Pubitemid 38950186)
24. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Böcker D, Breithardt G, Haverkamp W, Borggrefe M,: Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: A randomised trial. Lancet 2002; 360: 1275-1279. (Pubitemid 35284617)
25. Sung JR,: Facilitating electrical cardioversion of persistent atrial fibrillation by antiarrhythmic drugs: Update on clinical trial results. Card Electrophysiol Rev 2003; 7: 300-303.
26. Hohnloser SH, Zabel M,: Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992; 70: 3A-10A.
27. Mazzocca G, Corbucci G, Venturini E, Becuzzi L,: Is pretreatment with ibutilide useful for atrial fibrillation cardioversion when combined with biphasic shock? J Cardiovasc Med 2006; 7: 124-128. (Pubitemid 44159508)
28. Oral H, Souza JJ, Michaud GF, Knight BP,., Goyal R, Strickberger SA, Morady F,: Facilitating transthoracic cardioversion of atrial fibrillation with Ibutilide pretreatment. N Engl J Med 1999; 340: 1849-1854. (Pubitemid 29272664)
29. Dalzell GWN, Anderson J, Adgey AAJ,: Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med 1990; 76: 903-913. (Pubitemid 20294241)
30. Walsh SJ, McCarty D, McClelland AJ, Owens CG, Trouton TG, Harbinson MT, O'Mullan S, McAllister A, McClements BM, Stevenson M, Dalzell GW, Adgey AA,: Impedance compensated biphasic waveforms for transthoracic cardioversion of atrial fibrillation: A multi-centre comparison of antero-apical and antero-posterior pad positions. Eur Heart J 2005; 26: 1298-1302. Epub 2005 Apr 11. (Pubitemid 41435460)
31. Hayashi M, Tanaka K, Kato T, Morita N, Sato N, Yasutake M, Kobayashi Y, Takano T,: Enhancing electrical cardioversion and preventing immediate reinitiation of haemodynamically deleterious atrial fibrillation with class III drug pretreatment. J Cardiovasc Electrophysiol 2005; 16: 740-747. (Pubitemid 40994607)
32. Miracapillo G, Costoli A, Addonisio L, Severi S,: Initial energy for biphasic external electrical cardioversion of atrial fibrillation. Ital Heart J 2005; 6: 757-760.
33. Glover BM, Walsh SJ, McCann CJ, Moore MJ, Manoharan G, Dalzell GW, McAllister A, McClements B, McEneaney DJ, Trouton TG, Mathew TP, Adgey AA,: Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. Heart 2008; 94: 884-887. Epub 2007 Jun 25. (Pubitemid 351914699)
34. Zehender M, Meinertz T, Faber T, Caspary A, Jeron A, Bremm K, Just H,: Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. J Am Coll Cardiol 1997; 29: 1028-1034. (Pubitemid 27149577)
35. Manz M, Pfeiffer D, Jung W, Lueritz B,: Intravenous treatment with magnesium in recurrent persistent ventricular tachycardia. New Trends in Arrhythmias 1991; 7: 437-442.
36. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, Stern S,: Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392-397. (Pubitemid 18060048)
37. Gottlieb SS, Fisher ML, Pressel MD, Patten RD, Weinberg M, Greenberg N,: Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. Am Heart J 1993; 125: 1645-1650. (Pubitemid 23169479)
38. Barros LFM, Da-Luz PL, Silveira MC, Chagas ACP, Pileggi F,: Ventricular fibrillation in acute experimental myocardial ischemia: Protection by magnesiumsulfate. Braz J Med Biol Res 1988; 21: 791-799.
39. Fanning WJ, Thomas CS, Roach A, Tomichek R, Alford WC, Stoney WS,: Prophylaxis of atrial fibrillation with magnesium sulphate after coronary artery bypass grafting. Ann Thorac Surg 1991; 52: 529-533. doi:.
40. Maslow AD, Regan MM, Heindle S, Panzica P, Cohn WE, Johnson RG,: Postoperative atrial tachyarrhythmias in patients undergoing coronary artery bypass graft surgery without cardiopulmonary bypass: A role for intraoperative magnesium supplementation. J Cardiothorac Vasc Anesth 2000; 14: 524-530. doi:.
41. Alghamdi AA, Al-Radi OO, Latter DA,: Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: A systematic review and meta-analysis. J Card Surg 2005; 20: 293-299. doi:. (Pubitemid 40675685)
42. Pu J, Zhang C, Quan X, Zhao G, Lv J, Li B, Bai R, Liu N, Ruan Y, He B,: Effects of potassium aspartate and magnesium on ventricular arrhythmia in ischemia-reperfusion rabbit heart. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 517-519.
43. Stiles MK, Sanders P, Disney P, Brooks A, John B, Lau DH, Shashidhar, Wilson L, Mackenzie L, Young GD,: Differential effects of intravenous magnesium on atrioventricular node conduction in supraventricular tachycardia. Am J Cardiol 2007 15; 100: 1249-1253. Epub 2007 Aug 6. (Pubitemid 47505226)
44. Etienne Y, Blanc JJ, Grall JY, Boschat J, Gilard M, Houel JF, Penther P,: Electrophysiological effects of intravenous magnesium sulfate in man. Arch Mal Coeur Vaiss 1987; 80: 1327-1332. (Pubitemid 18041299)
45. Rasmussen HS, Thomsen PE,: The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. Clin Cardiol 1989; 12: 85-90. (Pubitemid 19057508)
46. Christiansen EH, Frost L, Andreasen F, Mortensen P, Thomsen PE, Pedersen AK,: Dose-related cardiac electrophysiological effects of intravenous magnesium. A double-blind placebo-controlled doseresponse study in patients with paroxysmal supraventricular tachycardia. Europace 2000; 2: 320-326.
47. Yamamoto H, Bando S, Nishikado A, Nishimura N, Akiyama K, Nouzu N, Mori H,: Electrophysiological effects of magnesium sulfate on human conduction system. Kokyu To Junkan 1989; 37: 77-81. (Pubitemid 19033983)
48. DiCarlo LA Jr, Morady F, de Buitleir M, Krol RB, Schurig L, Annesley TM,: Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol 1986; 7: 1356-1362. (Pubitemid 16100360)
49. Kulick DL, Hong R, Ryzen E, Rude RK, Rubin JN, Elkayam U, Rahimtoola SH, Bhandari AK,: Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease. Am Heart J 1988; 115: 367-373. (Pubitemid 18046502)
50. Olsson SB,: Nature of cardiac arrhythmias and electrolyte disturbances. Role of potassium in atrial fibrillation. Acta Med Scand Suppl 1981; 647: 33-37. (Pubitemid 11058780)
51. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA,: Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: Roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997; 96: 3710-3720. (Pubitemid 27513453)
52. Ehrlich JR, Cha TJ, Zhang L, Chartier D, Villeneuve L, Hebert TE, Nattel S,: Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol 2004; 557: 583-597. (Pubitemid 38807396)
53. Allessie M, Ausma J, Schotten U,: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246. (Pubitemid 34327903)
54. Kim SK, Pak HN, Park JH, Ko KJ, Lee JS, Choi JI, Choi DH, Kim YH,: Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace 2009; 11: 1632-1638.
55. Disertori M, Lombardi F, Barlera S, Latini R, Maggioni AP, Zeni P, Di Pasquale G, Cosmi F, Franzosi MG,; GISSI-AF Investigators: Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J. 2010; 159: 857-863.
56. Gullestad L, Birkeland K, Mølstad P, Høyer MM, Vanberg P, Kjekshus J,. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol 1993; 16: 429-434. (Pubitemid 23137829)
57. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS,. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001; 79: 287-291. (Pubitemid 32673692)
58. Resnekov L,: High-energy electrical current and myocardial damage. Med Instrum 1978; 12: 24-26. (Pubitemid 8296849)
59. Simon C, Roscitano A, Capuano F, Benedetto U, Di Nucci G, Tonelli E, Sinatra R,. Effect of topic defibrillation on serum markers of myocardial damage. Interact Cardiovasc Thorac Surg 2006; 5: 75-77. (Pubitemid 43200175)
60. Brugada P,: Magnesium: An antiarrhythmic drug, but only against very specific arrhythmias. Eur Heart J 2000; 21: 1116. (Pubitemid 30438632)